Completed × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Tacrolimus × Clear all
NCT01384513 2026-04-15

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Thomas Jefferson University

Phase 2 Completed
40 enrolled 15 charts
NCT02220985 2025-06-04

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

Fred Hutchinson Cancer Center

Phase 2 Completed
84 enrolled
NCT01350245 2025-05-16

Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor

Thomas Jefferson University

Phase 2 Completed
28 enrolled 10 charts
NCT00611351 2023-10-23

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

University of Nebraska

Phase 2 Completed
5 enrolled 10 charts
NCT03096782 2023-10-11

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

M.D. Anderson Cancer Center

Phase 2 Completed
6 enrolled 10 charts
NCT02661035 2023-09-21

Allo HSCT Using RIC for Hematological Diseases

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
156 enrolled
NCT01951885 2023-09-11

Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention

Case Comprehensive Cancer Center

Phase 3 Completed
101 enrolled 28 charts
NCT02960646 2023-02-16

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
11 enrolled
NCT00423514 2022-12-27

Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
38 enrolled 12 charts
NCT00860574 2021-06-22

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia

Fred Hutchinson Cancer Center

Phase 2 Completed
96 enrolled 15 charts
NCT02129582 2021-05-07

Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies

Case Comprehensive Cancer Center

Phase 1 Completed
14 enrolled
NCT00489203 2021-02-03

Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
140 enrolled
NCT01010217 2020-03-25

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

M.D. Anderson Cancer Center

Phase 2 Completed
176 enrolled 18 charts
NCT00053989 2020-02-10

NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

Roswell Park Cancer Institute

Phase 2 Completed
41 enrolled 13 charts
NCT00789776 2020-01-31

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 1/2 Completed
41 enrolled 14 charts
NCT00089011 2020-01-29

Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
150 enrolled 14 charts
NCT00006350 2019-11-04

Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

University of Maryland, Baltimore

Phase 2 Completed
NCT00105001 2019-10-30

Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
210 enrolled 15 charts
NCT01529827 2019-09-24

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Roswell Park Cancer Institute

Phase 2 Completed
94 enrolled 11 charts
NCT02208037 2019-01-23

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 2 Completed
279 enrolled 28 charts
NCT01789255 2018-07-24

Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies

National Cancer Institute (NCI)

Phase 2 Completed
12 enrolled 11 charts
NCT01246206 2018-06-18

Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
21 enrolled 13 charts
NCT00301951 2017-10-12

Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

University of California, San Francisco

Phase 1 Completed
7 enrolled
NCT00448357 2017-07-17

LCCC0510

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Completed
54 enrolled 17 charts
NCT00448201 2017-05-30

Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

UNC Lineberger Comprehensive Cancer Center

Phase 2 Completed
71 enrolled 12 charts
NCT00513474 2017-05-25

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Massachusetts General Hospital

Phase 1 Completed
46 enrolled 11 charts
NCT00049504 2017-05-17

Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
53 enrolled 10 charts
NCT01471067 2017-04-28

Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
33 enrolled
NCT00104975 2016-12-15

Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Yale University

Phase 1 Completed
20 enrolled
NCT00134004 2015-10-06

Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
210 enrolled 10 charts
NCT00589563 2014-09-10

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

City of Hope Medical Center

Phase 2 Completed
32 enrolled 24 charts
NCT00003572 2014-05-02

Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
20 enrolled
NCT00782379 2013-11-21

Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer

Northside Hospital, Inc.

Phase 2 Completed
20 enrolled 16 charts
NCT00304018 2013-08-14

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

University of California, San Francisco

Phase 1 Completed
5 enrolled
NCT00004255 2013-07-10

Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation

National Cancer Institute (NCI)

Phase 2/3 Completed